Form 15-12B Principia Biopharma Inc.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 15
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 001-38653
Principia Biopharma Inc.
(Exact name of registrant as specified in its charter)
220 East Grand Avenue
South San Francisco, California 94080
(650) 416-7700
(Address, including zip code, and telephone number, including area code, of registrants principal executive offices)
Common Stock, par value $0.0001 per share
(Title of each class of securities covered by this Form)
None
(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
Rule 12g-4(a)(1) |
☒ | |||||
Rule 12g-4(a)(2) |
☐ | |||||
Rule 12h-3(b)(1)(i) |
☒ | |||||
Rule 12h-3(b)(1)(ii) |
☐ | |||||
Rule 15d-6 |
☐ | |||||
Rule 15d-22(b) |
☐ |
Approximate number of holders of record as of the certification or notice date: One (1).
Pursuant to the requirements of the Securities Exchange Act of 1934, Principia Biopharma Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.
Date: October 8, 2020 |
By: | /s/ John Reed | ||||
Name: John Reed | ||||||
Title: President and Chief Executive Officer |
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Purple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
- VTG Enhances Digital Transformation and Cloud Capabilities with Acquisition of Vana Solutions
- Fixing of coupon rates - Nykredit Realkredit A/S
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!